Registry for patients with inflammatory breast cancer and MRD testing
Multi-center MRD Registry for Inflammatory Breast Cancer
This study is looking at patients with inflammatory breast cancer to see how often they test positive for minimal residual disease before surgery and how this affects their treatment and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT06966050 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect data from participants diagnosed with inflammatory breast cancer (IBC) who may have undergone minimal residual disease (MRD) testing and are planning for surgery. The primary objective is to determine the incidence of MRD positivity before surgery, while secondary objectives include evaluating the feasibility of multi-institutional data collection, assessing the relationship between MRD and pathologic response, and understanding the impact of MRD results on patients' quality of life. Participants will also provide longitudinal MRD data to track recurrence and the effects of adjuvant therapies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a clinical diagnosis of stage III or IV inflammatory breast cancer who have undergone MRD testing.
Not a fit: Patients who are not diagnosed with inflammatory breast cancer or those who have already undergone breast surgery for their diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of MRD in IBC and improve patient management strategies.
How similar studies have performed: While the approach of collecting MRD data in IBC is relatively novel, similar studies in other cancer types have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female or males ≥18 years of age with the ability to understand and sign a written * Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC). * Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database. * Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer. * Participants must be English-speaking. Exclusion Criteria: \-
Where this trial is running
Houston, Texas
- MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Sadia Saleem, MD — M.D. Anderson Cancer Center
- Study coordinator: Sadia Saleem, MD
- Email: ssaleem@mdanderson.org
- Phone: 281-566-1900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.